D. Garsed

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

S. Shah, D. Bowtell, S. Nik-Zainal, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.